Detection method and kit for detecting heparin or low-molecular heparin in blood sample

By adding coagulation substances to the whole blood sample to coagulate and calculating the coagulation strength difference, the problem of inaccurate detection results of heparin or low molecular weight heparin in the prior art is solved, and a more accurate, fast and economical detection effect is achieved, which is suitable for clinical applications.

CN119619482APending Publication Date: 2025-03-14XIANJU BAIYI MEDICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411769425.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-04
Publication Date
2025-03-14

AI Technical Summary

Technical Problem

When monitoring the anticoagulation effect of heparin or low-molecular heparin in the prior art, the results are not accurate enough, there are many influencing factors and the data are unreliable, resulting in deviations in clinical judgment.

Method used

The whole blood sample is used for detection, and the coagulation substance is added to the blood sample to coagulate, and the envelope area is calculated as the coagulation intensity value by using the integral method. By comparing the difference in coagulation intensity of heparin or low molecular weight heparin and the content of heparin or low molecular weight heparin is calculated.

Benefits of technology

The accuracy of the test results is improved, fully reflecting the inhibitory effect of heparin or low-molecular heparin on thrombosis. The test results are fast and low-cost, and are suitable for clinical promotion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119619482A_ABST
    Figure CN119619482A_ABST
Patent Text Reader

Abstract

The invention provides a method for detecting heparin or low-molecular heparin in a blood sample, which comprises the following steps: 1) adding a blood coagulation substance into the blood sample to coagulate the blood sample, and calculating an envelope area as a coagulation strength value S2; the method comprises the following steps: adding a heparin-removed or low-molecular heparin-removed substance into the same blood sample, adding a blood coagulation substance into the blood sample to coagulate the blood sample, and calculating an envelope area as a coagulation strength value S1; the content D1 of heparin or low-molecular heparin in the blood sample is equal to K * (S1-S2); and (2) calibrating by using a calibration blood sample of heparin or low-molecular heparin with known content, and calculating a K value. According to the invention, a whole blood sample is adopted, and the detection result fully reflects the effect result of inhibiting thrombosis by the content of heparin or low-molecular heparin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and more particularly to a method and a kit for detecting heparin or low molecular weight heparin in a blood sample. Background Art

[0002] The human body possesses a highly efficient coagulation mechanism to prevent blood from leaking out of damaged blood vessels. However, under pathological conditions, the circulatory system can form thrombi through this mechanism, leading to thromboembolic diseases. Today, thrombotic diseases (such as myocardial infarction and cerebral infarction) are associated with high morbidity, disability, and mortality, and have become the leading cause of death worldwide. Heparin-based anticoagulants were the first anticoagulants used clinically, ushering in a new era in anticoagulant therapy and improving the treatment of thrombotic diseases. Heparin, the earliest anticoagulant used clinically, is widely used in clinical practice, primarily for acute coronary syndromes, extracorporeal circulation (CPB), and extracorporeal membrane oxygenation (ECMO). It is also used in the prevention and treatment of thromboembolic events, including hip fractures, perioperative anticoagulation for surgical and gynecological procedures, deep vein thrombosis of the limbs, pulmonary infarction, superficial vein thrombosis, stroke, and myocardial infarction.

[0003] The clinical significance of heparin testing: The main disadvantages of heparin are its low bioavailability, significant inter-individual variability in efficacy, a narrow safe therapeutic window, and a dose-dependent half-life. Some patients may even develop heparin resistance due to improper dosing. Significant clinical practice variations exist in monitoring heparin anticoagulation, anticoagulation reversal, and the use of alternative anticoagulants. To more accurately and rapidly assess the anticoagulant effect of heparin and reduce the occurrence of complications, it is crucial to select appropriate monitoring methods and effective levels. Currently, the primary clinical indicators for monitoring the anticoagulant effect of heparin are the activated partial prothrombin time (APTT) and the activated whole blood clotting time (ACT). Both assays are qualitative and subject to numerous influencing factors, such as hemodilution, abnormal liver function, coagulation factor deficiency, thrombocytopenia, lupus anticoagulant, and antiphospholipid syndrome, which can lead to unreliable data and clinical bias. In 2014, the ELSO guidelines included anti-Xa activity as a criterion for dose adjustment of heparin and low molecular weight heparin. The normal anti-Xa level in a normal person is less than 0.1 IU / mL. The prophylactic and therapeutic range for unfractionated heparin is 0.1–0.2 IU / mL, and the effective therapeutic concentration should be controlled between 0.35 and 0.75 IU / mL. For low-molecular-weight heparin prophylaxis, the anti-Xa level is controlled between 0.1 and 0.3 IU / mL; for deep vein thrombosis treatment, the anti-Xa level is controlled between 0.5 and 1.0 IU / mL. Heparin is a sulfated mucopolysaccharide that binds to antithrombin III (AT-III), significantly enhancing its inhibitory effect on thrombin and other coagulation factors. Heparin is widely used clinically for the prevention and treatment of related diseases, particularly as an anticoagulant during surgery. Excessive heparin use can cause side effects such as heavy bleeding, thrombocytopenia, hyperkalemia, and osteoporosis, so heparin dosage must be strictly monitored.

[0004] Heparin is divided into unfractionated heparin (UFH) and low molecular weight heparins (LMWHs). They are commonly used heparin anticoagulants in clinical practice. The former is used in surgeries such as CPB, hemodialysis, and stent placement, while the latter is widely used in the prevention and treatment of venous thrombosis.

[0005] Use a thromboelastograph to measure the effective blood levels of heparin and low-molecular-weight heparin anticoagulants, ensuring that medication use remains within a reasonable and effective range. The effective blood level refers to the combined antithrombotic effect of heparin or low-molecular-weight heparin and all other blood factors. For example, different patients with the same 1 IU / ml heparin level will experience different antithrombotic effects. This is because: 1) Heparin or low-molecular-weight heparin binds to antithrombin 3 (AT-III) in the blood to amplify its anticoagulant effect by approximately a thousand-fold, but AT-III levels vary significantly between individuals; 2) In addition to AT-III, thrombin and fibrin are also required for thrombosis formation. These factors are produced in the liver and also vary significantly between individuals. Improper use of anticoagulants can lead to hemorrhagic adverse events, making effective blood level measurement crucial. Summary of the Invention

[0006] In view of the shortcomings of the existing technology, the present invention provides a method for detecting heparin or low molecular weight heparin in a blood sample. The detection method uses a whole blood sample and its detection results are more accurate.

[0007] To achieve the above object, the present invention provides the following technical solutions:

[0008] A method for detecting heparin or low molecular weight heparin in a blood sample comprises the following steps:

[0009] 1) Testing of blood samples containing heparin or low molecular weight heparin: A coagulant is added to a blood sample to cause the blood sample to coagulate. The reaction curve is integrated to calculate the envelope area as the coagulation strength value, recorded as S2. A substance without heparin or low molecular weight heparin is added to the same blood sample. The coagulant is also added to the blood sample to cause the blood sample to coagulate. The reaction curve is integrated to calculate the envelope area as the coagulation strength value, recorded as S1. The heparin or low molecular weight heparin content in the blood sample D1 = K × (S1-S2);

[0010] 2) Calibrate using a calibration blood sample containing heparin or low molecular weight heparin with a known content of D2: add the coagulation substance to the calibration blood sample to cause the calibration blood sample to coagulate, and integrate the change curve of the reaction to calculate the envelope area as the coagulation strength value, recorded as S4; add the deheparinized or low molecular weight heparinized substance described in step 1) to the same calibration blood sample, and at the same time add the coagulation substance described in step 1) to the calibration blood sample to cause the calibration blood sample to coagulate, and integrate the change curve of the reaction to calculate the envelope area as the coagulation strength value, recorded as S3; according to K = D2 / (S3-S4).

[0011] The technical solution of the present invention uses a whole blood sample, that is, all factors involved in blood coagulation in the whole blood are involved in the formation of thrombus, and its test results fully reflect the effect of heparin or low molecular weight heparin content in inhibiting thrombosis; since all blood components and factors are involved in the test, the test results can be obtained quickly, and since the thromboelastography device is widely used in hospitals, it is easy to use and low cost, and is suitable for clinical promotion. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 This is the low molecular weight heparin test report of the present invention.

[0013] Figure 2 This is a schematic diagram of a single channel containing heparin or low molecular weight heparin in the low molecular weight heparin test report of the present invention.

[0014] Figure 3 This is a schematic diagram of a single channel for removing heparin or low molecular weight heparin from the low molecular weight heparin test report of the present invention. DETAILED DESCRIPTION

[0015] The present invention will be further described with reference to the accompanying drawings.

[0016] The present invention discloses a quantitative detection method for heparin or low molecular weight heparin, used to analyze and evaluate the heparin or low molecular weight heparin content in a blood sample. The method utilizes a coagulation method, which involves using a thromboelastometry instrument to measure the coagulation time and coagulation strength of a blood sample as it transitions from a liquid state to a solid state, as detection parameters. The coagulation strengths of a blood sample containing heparin or low molecular weight heparin are measured by thromboelastometry and compared with those of the same blood sample after adding a heparin or low molecular weight heparin removal reagent. The heparin or low molecular weight heparin content in the blood sample is calculated and determined. The blood sample is whole blood. The detection method comprises the following steps: 1) measuring the coagulation strength of a heparin or low molecular weight heparin blood sample; 2) measuring the coagulation strength of the same blood sample after removing the heparin or low molecular weight heparin from the blood sample; and 3) calculating the difference between the two coagulation strengths of the same blood sample to determine the heparin or low molecular weight heparin content in the blood sample.

[0017] The coagulation strength of a blood sample refers to the envelope area (integrated) of the coagulation curve of the blood sample detected by an elastogram. A larger envelope area indicates a greater coagulation strength. The envelope area is negatively correlated with the heparin or low molecular weight heparin content in the blood sample and has a good linear relationship.

[0018] The present invention also provides a test kit and a method for preparing a calibration blood sample for use in the test, which are used to calibrate the thromboelastometry detection system when quantitatively detecting heparin or low-molecular-weight heparin. Compared with previous detection methods, this method uses a whole blood sample, meaning that all factors involved in blood coagulation in the entire blood are involved in thrombus formation. The detection results fully reflect the effect of heparin or low-molecular-weight heparin content in inhibiting thrombus formation. However, all previous detection methods for heparin or low-molecular-weight heparin do not use blood sample coagulation to form thrombi as the detection result, so their results cannot fully reflect the full range of factors that heparin or low-molecular-weight heparin inhibits thrombus formation. Instead, they only detect a few blood factors, such as anticoagulant factor 10 (FXa), which can also obtain heparin or low-molecular-weight heparin content results. However, such results ignore important factors required for thrombus formation, such as thrombin generation and fibrin production, which can cause these heparin or low-molecular-weight heparin detection results to deviate from clinical symptoms. The test results of the present invention are all involved in the test of blood factors, and the results can be obtained quickly. Also, since the thromboelastography device is widely used in hospitals, it is easy to use and low in cost, and is suitable for clinical promotion.

[0019] The technical solution of the present invention is to design a method for measuring heparin or low molecular weight heparin by measuring the coagulation strength of a blood sample, comprising the following steps:

[0020] Step 1): Testing a blood sample containing heparin or low molecular weight heparin: A coagulation substance is added to a first blood sample to cause the blood sample to coagulate, and the reaction intensity of the first blood sample from the start of coagulation after the addition of the coagulation substance to the end of coagulation is obtained. The end of coagulation refers to the end of the coagulation reaction, that is, the coagulation reaction ends when the reaction curve reaches a flat state when using a coagulation analyzer and the MA value shown in the thromboelastography test no longer changes. The envelope area of ​​the reaction change curve is calculated by integration as the intensity S2 of the coagulation reaction, and the integrated area refers to the envelope area of ​​the reaction curve from the start of the coagulation reaction to the end of the reaction (the coagulation intensity is the same as described below);

[0021] Coagulants refer to substances that can cause plasma or whole blood to coagulate, and may include thrombin, hemocoagulase (derived from snakes), tissue factor, phospholipids, ellagic acid, kaolin, calcium, magnesium, and zinc ions. These substances can cause blood samples to coagulate. The kit provided in this case can be used to implement this step. The kit can use the following components: thrombin and hemocoagulase (derived from snakes) can coagulate blood samples through enzymatic reactions. Their coagulation speed is fast and the test results can be obtained quickly. The thrombin can be 2-10 IU / ml and the hemocoagulase can be 5-15 IU / ml; the tissue factor is an exogenous coagulation factor, and kaolin and ellagic acid are endogenous coagulation factors. They activate blood coagulation factors to cause the sample to coagulate, and the coagulation speed is second. The tissue factor content can be 0.01-0.3 mmol; the kaolin and ellagic acid content can be 0.5-2 mmol; phospholipids and divalent ions have a slower coagulation speed, the phospholipid content is 0.2-0.5 mmol, and the content of divalent ions such as calcium is 0.1-0.7 mmol. The coagulation substances can be used alone or in combination based on clinical and cost requirements. The kit also includes a buffer solution, which provides a suitable pH value for the reagent. The buffer solution can be a hydrochloric acid-Tris buffer solution, and the suitable pH value is 6.8-7.5. The kit also includes a preservative, which can be PC300, and the dosage can be 0.1%.

[0022] Step 2): A substance that removes heparin or low molecular weight heparin is added to the same blood sample, and the detection process of step 1 is then repeated to obtain a reaction intensity of the blood sample, which is represented by S1. The substance that removes heparin or low molecular weight heparin or low molecular weight heparin can be heparinase, an alkaline substance such as protamine, toluidine blue, or an alkaloid. The heparinase can degrade the heparin or low molecular weight heparin in the sample, thereby removing the heparin or low molecular weight heparin in the second blood sample. The alkaline substance can neutralize the heparin or low molecular weight heparin containing acidic groups, thereby inactivating the heparin or low molecular weight heparin.

[0023] The heparinase content of the kit in this step can be 0.5-8 IU / ml, the protamine content can be 10-30 mg / ml, and the toluidine blue content can be 1-5 mg / ml. The kit in this step also includes the same blood sample coagulation substance as the reagent in step 1, and is consistent with the above-mentioned step 1.

[0024] Thrombin and hemocoagulase (derived from snake venom extraction) The thrombin can be 2-10 IU / ml, and the hemocoagulase can be 5-15 IU / ml; the tissue factor is an exogenous coagulation factor, and kaolin and ellagic acid are endogenous coagulation factors. They activate blood coagulation factors to cause the sample to coagulate, and the coagulation speed is second only to the thrombin content. The tissue factor content can be 0.01-0.3 mmol; the kaolin and ellagic acid content can be 0.5-2 mmol; phospholipids and divalent ions have a slower coagulation speed, the phospholipid content is 0.2-0.5 mmol, and the content of divalent ions such as calcium is 0.1-0.7 mmol.

[0025] The kit also includes a buffer solution, which provides a suitable pH value for the reagent. The buffer solution can be a hydrochloric acid-Tris buffer solution, and the suitable pH value is 6.8-7.5. The kit also includes a preservative, which can be PC300, and the dosage can be 0.1%.

[0026] Step 3): Calculate the heparin or low molecular weight heparin content in the blood sample using the formula D = K × (S1 - S2), where D is the heparin or low molecular weight heparin content in the blood sample, S1 is the coagulation strength value of the heparin or low molecular weight heparin-free blood sample, and S2 is the coagulation strength value of the same sample containing heparin or low molecular weight heparin. K is the proportionality constant, and the K value is obtained using the following calibration procedure.

[0027] Step 4): Calibration step: Because the coagulation strength of a blood sample is inversely proportional to the heparin or low molecular weight heparin content in the blood sample and the relationship is linear, the calibration step uses a calibration blood sample with a known heparin or low molecular weight heparin content. The known heparin content blood sample is prepared by adding a known amount of heparin to a normal blood sample. This step provides a preparation method. For example, a 0.6 IU / ml heparin calibration blood sample is prepared by pipetting 0.94 ml of a normal blood sample into a test tube and then adding 0.06 ml of a 1000 IU / ml heparin solution to the test tube to obtain 1 ml of a 0.6 IU / ml heparin calibration blood sample.

[0028] The normal blood sample mentioned above refers to a blood sample that has a normal result when tested on a thrombelastograph using standard cup reagent. The preparation of a low-molecular-weight heparin follows the same steps as above, except that the heparin is replaced with low-molecular-weight heparin. The K value is determined by testing a calibration blood sample with a known heparin concentration on an elastograph. For example, using a blood sample with 0.6 IU / mL heparin, S3 and S4 are measured, resulting in K = 0.6 / (S3 - S4). The ATEG thrombelastograph automatically performs this calibration calculation.

[0029] This case provides calibrators of heparin and low molecular weight heparin with known concentrations.

[0030] The normal blood sample refers to a blood sample having a normal blood sample result when the thrombelastograph to be calibrated is tested using a common cup.

[0031] The biggest difference from other detection methods is that the test includes all factors in the blood sample that affect thrombosis, while any other method for detecting heparin or low molecular weight heparin only detects some factors in the blood sample, such as APTT, ACT, and anti-Xa. In addition, the blood sample does not coagulate during the entire detection process, so there is no thrombosis. Therefore, the results of these methods are bound to be inaccurate. This is because the real effect of heparin or low molecular weight heparin is anti-thrombosis, and using a thromboelastogram to detect heparin or low molecular weight heparin is a real test of its anti-thrombotic results, and all components in the blood sample are fully involved in thrombosis.

[0032] For example, clinical use of anti-Xa only measures the quantitative results of the effects of heparin or low molecular weight heparin on factor 10 (FXa). It does not measure prothrombin and fibrinogen, important factors involved in thrombosis, and clotting factor 10 (FXa) itself cannot form thrombi. Prothrombin and fibrinogen are synthesized by the liver and there are individual differences even in normal people. In disease conditions (such as liver disease, infection, chronic disease, etc.), individual differences are even greater. If the true effective results of heparin or low molecular weight heparin on thrombosis cannot be accurately measured, clinical bleeding events will occur. Conversely, if the dosage of heparin or low molecular weight heparin is insufficient, thrombotic adverse events will occur. Thromboelastography plays a vital role in perioperative (preoperative, intraoperative, and postoperative) anticoagulation monitoring, especially after cardiac, vascular, or orthopedic surgery using heparin, to detect heparin residues and screen for causes of postoperative bleeding. Therefore, the use of thromboelastography to detect anticoagulation of heparin and low molecular weight heparin can truly and accurately achieve the dosage provided in the treatment guidelines, thereby ensuring patient safety, avoiding the occurrence of adverse medical events, reducing the burden of medical insurance, and benefiting multiple parties. Specific embodiment:

[0034] Example 1:

[0035] Step 1): Tissue factor was added to a pH 7.2 hydrochloric acid-Tris buffer to a concentration of 0.05 mmol, thrombin was added to a concentration of 3 IU / ml, ellagic acid was added to a concentration of 0.5 mmol, calcium chloride was added to a concentration of 0.1 mmol, and the preservative PC300 was added to the above reagents to a concentration of 0.1% to obtain reagent A. 20 μL of the above reagent A was added to a 340 μL whole blood sample. The sample coagulated within 15 minutes, and the relative coagulation strength S2 = 3.13 (S2 is the coagulation strength of the blood sample containing heparin or low molecular weight heparin) was obtained by elastography (whole blood sample). Figure 2 As shown;

[0036] Step 2): Tissue factor was added to a pH 7.2 hydrochloric acid-Tris buffer to a concentration of 0.05 mmol, thrombin to a concentration of 3 IU / ml, ellagic acid to a concentration of 0.5 mmol, calcium chloride to a concentration of 0.1 mmol, and the preservative PC300 to a concentration of 0.1% to obtain reagent B. Reagent A of this kit was first added to a 340 μl blood sample, followed by 20 μl of reagent B. The sample coagulated within 15 minutes, and the heparin- or low-molecular-weight heparin-removed sample coagulation strength S1 was measured by elastography (whole blood sample) to obtain a coagulation strength of 13.22 (S1 is the coagulation strength of the heparin- or low-molecular-weight heparin-removed blood sample). Figure 3 As shown;

[0037] Step 3): Calculation of results: Calculation of the heparin or low molecular weight heparin content in the blood sample: D = K × (S1-S2), where D is the heparin or low molecular weight heparin content in the blood sample, S1 is the coagulation strength value of the blood sample without heparin or low molecular weight heparin, and S2 is the coagulation strength value of the same sample containing heparin or low molecular weight heparin; K is the proportional constant. Under the detection conditions used in steps 1) and 2) above, K = 0.0595, so D = 0.0595*(13.22-3.13) = 0.6, which means that the heparin or low molecular weight heparin content in the blood sample is measured to be 0.6 IU / mL. The value of K in actual use is obtained through the following calibration steps;

[0038] Calibration procedure: Before using the thromboelastograph for the first time to test heparin or low molecular weight heparin content or before using a different batch of reagents, a calibration procedure is required. The specific method is as follows: Pipette 0.97 ml of normal blood sample into a test tube, then add 0.03 ml of 1000 IU / ml heparin solution to the test tube to obtain 1 ml of 0.3 IU / ml heparin calibration blood sample; repeat steps 1) to 2) on the elastograph using the calibration blood sample with known heparin content;

[0039] Step 1): Tissue factor was added to a pH 7.2 hydrochloric acid-Tris buffer to a concentration of 0.05 mmol, thrombin was added to a concentration of 3 IU / ml, ellagic acid was added to a concentration of 0.5 mmol, calcium chloride was added to a concentration of 0.1 mmol, and PC300, a preservative, was added to a concentration of 0.1% to obtain reagent A. 20 μl of reagent A was added to a 340 μl calibration blood sample. The calibration blood sample was coagulated, and the relative coagulation strength S4 was obtained by elastography (whole blood sample).

[0040] Step 2): Tissue factor was added to a pH 7.2 hydrochloric acid-Tris buffer to a concentration of 0.05 mmol, thrombin to a concentration of 3 IU / ml, ellagic acid to a concentration of 0.5 mmol, calcium chloride to a concentration of 0.1 mmol, and the preservative PC300 to a concentration of 0.1% to obtain Reagent B. Reagent A from this kit was first added to 340 μl of the same calibration blood sample, followed by 20 μl of Reagent B. The sample was allowed to clot, and the coagulation strength (S3) associated with heparin-depleted or low-molecular-weight heparin samples was measured using an elastogram (whole blood sample); this was based on K = 0.3 / (S3 - S4).

[0041] Thromboelastography is used to measure the dynamics of thrombus formation and to detect the effective thrombus inhibition effect of heparin or low molecular weight heparin.

[0042] The advantage of using thromboelastometry for quantitative detection of heparin and low molecular weight heparin is that the results are based on the strength of the thrombus after thrombus formation, which is inversely correlated with the heparin and low molecular weight heparin content in the blood sample.

[0043] The biggest difference from other detection methods is that the test includes all factors in the blood sample that affect thrombosis, while any other method for detecting heparin or low molecular weight heparin only detects some factors in the blood sample, such as APTT, ACT, and anti-Xa. In addition, the blood sample does not coagulate during the entire detection process, so there is no thrombosis. Therefore, the results of these methods are bound to be inaccurate. This is because the real effect of heparin or low molecular weight heparin is anti-thrombosis, and using a thromboelastogram to detect heparin or low molecular weight heparin is a real test of its anti-thrombotic results, and all components in the blood sample are fully involved in thrombosis.

[0044] Clinical evaluation:

[0045] Clinical evaluation approach: comparative research trials with similar products already marketed domestically.

[0046] 116 clinical blood samples were compared using the detection method of the present application and the anti-Xa method (using an instrument: a coagulometer) that has been approved for marketing.

[0047] A total of 116 samples were included in this study, with no samples excluded. Therefore, the actual number of valid samples in this study was 116, and the sample type was whole blood.

[0048] The results of the thromboelastometry (low molecular weight heparin) assay using the present method and kit were consistent with those of the approved anti-Xa assay kit (chromogenic substrate method) (coagulation method) in China. It can be concluded that there is no difference in the clinical performance of the two assay systems. The test data for the 116 samples are shown in Table 1:

[0049] Table 1

[0050]

[0051]

[0052]

[0053]

[0054] This application uses a new detection system for low molecular weight heparin, including a detection method and a detection reagent, which can be tested on an "elastograph instrument" instead of a "coagulometer." In the absence of a low molecular weight heparin detection instrument, an elastography instrument can be used to perform low molecular weight heparin testing, expanding the convenience of low molecular weight heparin testing.

[0055] In terms of detection principles, elastography instruments use the "normal elastic force detection method," while coagulometers use the "chromogenic substrate method," and the two have different detection principles. Traditional low-molecular-weight heparin detection instruments cannot detect the actual degree of blood coagulation. Therefore, they use an "indirect detection method" to measure heparin's effect on coagulation. However, individual heparin tolerance varies greatly, and the same amount of heparin may have a better anti-thrombotic effect in some individuals, but may cause bleeding in others. This application uses terminal detection, which directly evaluates heparin's effect on coagulation based on blood coagulation conditions, which can better assess heparin's actual effect.

[0056] The above description is merely a preferred embodiment of the present invention. The scope of protection of the present invention is not limited to the above embodiment. All technical solutions based on the concept of the present invention are within the scope of protection of the present invention. It should be noted that for those skilled in the art, various improvements and modifications that do not depart from the principles of the present invention should also be considered within the scope of protection of the present invention.

Claims

1. A method for detecting heparin or low molecular weight heparin in a blood sample, characterized in that: The steps include: 1) Blood sample test containing heparin or low molecular weight heparin: add coagulation substances to the blood sample to make the blood sample coagulate, and the change curve of the reaction is calculated by integration to calculate the envelope area as the coagulation strength value, recorded as S2; Add a substance without heparin or low molecular weight heparin to the same blood sample, and at the same time add the coagulation substance to the blood sample to make the blood sample coagulate. The change curve of the reaction is calculated by integration to calculate the envelope area as the coagulation strength value, recorded as S1; the heparin or low molecular weight heparin content in the blood sample D1 = K× (S1-S2); 2) Calibrate using a calibration blood sample with a known heparin or low molecular weight heparin content D2: add the coagulation substance to the calibration blood sample to make the calibration blood sample coagulate, and use an integral method to calculate the envelope area of ​​the reaction curve as the coagulation strength value, recorded as S4; add the de-heparinized or low molecular weight heparin substance described in step 1) to the same calibration blood sample, and at the same time add the coagulation substance described in step 1) to the calibration blood sample to make the calibration blood sample coagulate, and use an integral method to calculate the envelope area of ​​the reaction curve as the coagulation strength value, recorded as S3; according to K=D2 / (S3-S4).

2. The method for detecting heparin or low molecular weight heparin in a blood sample according to claim 1, characterized in that: The coagulation substances include thrombin, hemocoagulase, tissue factor, phospholipids, ellagic acid, kaolin, calcium, magnesium or zinc ions.

3. The method for detecting heparin or low molecular weight heparin in a blood sample according to claim 2, characterized in that: The coagulation substance is thrombin, and its concentration is 2 to 10 IU / ml; Alternatively, the coagulation substance is hemocoagulase, and its concentration is 5 to 15 IU / ml; Alternatively, the coagulation substance is tissue factor, and its concentration is 0.01 to 0.3 mmol; Alternatively, the coagulation substance is kaolin or ellagic acid, and its concentration is 0.5 to 2 mmol; Alternatively, the coagulation substance is phospholipid, and its concentration is 0.2-0.5 mmol; Alternatively, the coagulation substance is a divalent ion such as calcium, and its concentration is 0.1 to 0.7 mmol.

4. The method for detecting heparin or low molecular weight heparin in a blood sample according to any one of claims 1 to 3, characterized in that: The blood coagulation substance further comprises a buffer, and the buffer is a Tris-HCl buffer.

5. The method for detecting heparin or low molecular weight heparin in a blood sample according to claim 4, characterized in that: The pH of the buffer solution is 6.8-7.

5.

6. The method for detecting heparin or low molecular weight heparin in a blood sample according to claim 5, characterized in that: The blood coagulation substance also includes a preservative, and the preservative is PC300, and its mass percentage is 0.1%.

7. The method for detecting heparin or low molecular weight heparin in a blood sample according to claim 6, characterized in that: The substance for removing heparin or low molecular weight heparin includes heparinase or alkaline substances.

8. The method for detecting heparin or low molecular weight heparin in a blood sample according to claim 7, characterized in that: The concentration of the heparinase is 0.5-8 IU / ml.

9. The method for detecting heparin or low molecular weight heparin in a blood sample according to claim 7, characterized in that: The alkaline substance includes protamine, toluidine blue or alkaloids.

10. A kit for detecting heparin or low molecular weight heparin in a blood sample, characterized by: It includes coagulation substances, and substances without heparin or low molecular weight heparin; the coagulation substances include thrombin, thrombin, tissue factor, phospholipids, ellagic acid, kaolin, calcium, magnesium or zinc ion; the substances without heparin or low molecular weight heparin include heparinase or alkaline substances.